These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16225652)

  • 1. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma.
    Ludwig H; Spicka I; Klener P; Greil R; Adam Z; Gisslinger H; Tarkovács G; Linkesch W; Maniatis A; Morant R; Drach J; Kuhn I; Schuster J; Hinke A
    Br J Haematol; 2005 Nov; 131(3):329-37. PubMed ID: 16225652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience.
    Cohen AM; Meytes D; Many A; Brenner B; Aghai E; Shaklai M; Kaufman S; Shtalrid M; Attias D; Manor Y
    Isr J Med Sci; 1995 Oct; 31(10):604-10. PubMed ID: 7591683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon alfa-2b with VMCP compared to VMCP alone for induction and interferon alfa-2b compared to controls for remission maintenance in multiple myeloma: interim results.
    Ludwig H; Cohen AM; Huber H; Nachbaur D; Jungi WF; Senn H; Günczler P; Schüller J; Eckhardt S; Seewann HL
    Eur J Cancer; 1991; 27 Suppl 4():S40-5. PubMed ID: 1799476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Crowley JJ; Grogan TM; Finley P; Pugh RP; Barlogie B
    J Clin Oncol; 1994 Nov; 12(11):2405-14. PubMed ID: 7964957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized study comparing VMCP and MMPP in the treatment of multiple myeloma.
    Nagura E; Ichikawa A; Kamiya O; Kato R; Utsumi M; Tanaka M; Takeyama H; Shimizu K; Kobayashi M; Naito K; Nishiwaki H; Mizuno H; Hirabayashi N; Nitta M; Kato Y; Shibata T; Hotta T; Kawashima K; Saito H
    Cancer Chemother Pharmacol; 1997; 39(4):279-85. PubMed ID: 9025767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of vincristine, carmustine, melphalan, cyclophosphamide, prednisone (VBMCP) and interferon-alpha with melphalan and prednisone (MP) and interferon-alpha (IFN-alpha) in patients with good-prognosis multiple myeloma: a prospective randomized study. Greek Myeloma Study Group.
    Zervas K; Pouli A; Gregoraki B; Anagnostopoulos N; Dimopoulos MA; Bourantas K; Tzilianos M; Barbarousi D; Venetis E; Vyniou N; Maniatis A
    Eur J Haematol; 2001 Jan; 66(1):18-23. PubMed ID: 11168503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined alpha-2C-interferon/VMCP polychemotherapy versus VMCP polychemotherapy as induction therapy in multiple myeloma: a prospective randomized trial.
    Scheithauer W; Cortelezzi A; Fritz E; Kührer I; Polli E; Baldini L; Ludwig H
    J Biol Response Mod; 1989 Apr; 8(2):109-15. PubMed ID: 2659740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant interferon alfa-2C versus polychemotherapy (VMCP) for treatment of multiple myeloma: a prospective randomized trial.
    Ludwig H; Cortelezzi A; Scheithauer W; Van Camp BG; Kuzmits R; Fillet G; Peetermans M; Polli E; Flener R
    Eur J Cancer Clin Oncol; 1986 Sep; 22(9):1111-6. PubMed ID: 3536528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VMCP chemotherapy with or without interferon-alpha-2 in newly diagnosed patients with multiple myeloma.
    Preis P; Scheithauer W; Fritz E; Zielinski C; Kuehrer I; Cortelezzi A; Polli E; Baldini L; Pirker R; Kriegisch A
    Onkologie; 1989 Feb; 12(1):27-9. PubMed ID: 2654788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha for induction and maintenance in multiple myeloma: results of two multicenter randomized trials and summary of other studies.
    Ludwig H; Cohen AM; Polliack A; Huber H; Nachbaur D; Senn HJ; Morant R; Eckhardt S; Günczler P; Seewann HL
    Ann Oncol; 1995 May; 6(5):467-76. PubMed ID: 7669712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study.
    Salmon SE; Tesh D; Crowley J; Saeed S; Finley P; Milder MS; Hutchins LF; Coltman CA; Bonnet JD; Cheson B
    J Clin Oncol; 1990 Sep; 8(9):1575-84. PubMed ID: 2131793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage III myeloma. The Nagoya Myeloma Cooperative Study Group.
    Shimizu K; Kamiya O; Hamajima N; Mizuno H; Kobayashi M; Hirabayashi N; Takeyama H; Kato R; Kawashima K; Nitta M
    Jpn J Cancer Res; 1990 Dec; 81(12):1320-7. PubMed ID: 2126002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.
    Boccadoro M; Marmont F; Tribalto M; Avvisati G; Andriani A; Barbui T; Cantonetti M; Carotenuto M; Comotti B; Dammacco F
    J Clin Oncol; 1991 Mar; 9(3):444-8. PubMed ID: 1999714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superior efficacy of MMCP regimen compared with VMCP and MMPP regimens in the treatment of multiple myeloma.
    Mizuno H; Yamao H; Nagura E; Shimizu K; Kamiya O; Takeyama H; Nitta M; Wakita A; Ichikawa A; Kobayashi M; Kawashima K; Saito H;
    Intern Med; 2002 Apr; 41(4):290-4. PubMed ID: 11993789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma.
    Kabir AL; Rahman MJ; Begum M; Dipta TF; Baqui MN; Aziz A; Rahman F; Debnath RC; Habib MA
    Mymensingh Med J; 2012 Jan; 21(1):114-9. PubMed ID: 22314465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma.
    Oken MM; Kyle RA; Greipp PR; Kay NE; Tsiatis A; Gregory SA; Spiegel R J; O'Connell M J
    Leuk Lymphoma; 1996 Feb; 20(5-6):447-52. PubMed ID: 8833401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Erythropoietin in multiple myeloma].
    Pecherstorfer M; Schmoranzer F; Vesely M; Fortelny A; Baumgartner G
    Dtsch Med Wochenschr; 1990 Jul; 115(28-29):1096-9. PubMed ID: 2373040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study.
    Durie BG; Dixon DO; Carter S; Stephens R; Rivkin S; Bonnet J; Salmon SE; Dabich L; Files JC; Costanzi JJ
    J Clin Oncol; 1986 Aug; 4(8):1227-37. PubMed ID: 3525768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.